Objectives: Individuals with bipolar disorder (BPD) exhibit alterations in their phospholipid levels. It is unclear whether these alterations are a secondary consequence of illness state, or if phospholipids and illness risk overlap genetically. If the latter were true, then phospholipids might provide key insights into the pathophysiology of the illness. Therefore, we rank-ordered phospholipid classes by their genetic overlap with BPD risk in order to establish which class might be most informative in terms of increasing our understanding of illness pathophysiology.
with those that are disrupted in disease. Thus, the identification of endophenotypes for psychiatric illnesses should contribute to our understanding of illness pathophysiology. 5 Peripheral markers, such as serum-based lipid measurements, hold great promise as endophenotypes for two reasons. First, their underlying biochemical underpinnings are relatively well understood, particularly when compared to, for example, brain-or behavior-based phenotypes. Second, peripheral markers are easily obtainable at comparatively low cost. 6 These advantages are particularly appealing for BPD, a psychiatric illness that is ranked as one of the leading causes of disability and premature mortality worldwide, 7-9 but whose physiological underpinnings are still largely unknown.
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Lipids and their polyunsaturated fatty acids (PUFAs) constitute basic and essential components of all human cells, in terms of both structure, making up the major component of cell membranes, and function, playing a part in neurotransmission, receptor function, and eicosanoid biosynthesis. 11, 12 A number of lipidomic alterations have been noted in those with BPD and also major depressive disorder (MDD). 13 For example, increases in plasma levels of lipid peroxidation have been noted in euthymic adults with BPD 6 while decreases have been noted in adolescent BPD individuals.
14 It has been shown that essential PUFAs in red blood cell membranes, including arachadonic and docosahexaenoic acid (DHA), are reduced in BPD individuals in a manic phase 15 and in individuals with MDD
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, and that the fatty acid composition of phospholipids in serum is altered in those with MDD such that the arachadonic:eicosapentaenoic acid ratios are higher. 17, 18 Accordingly, a handful of studies suggest that administration of fatty acids may have benefits in the amelioration of mood symptoms.
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Brain-based findings, both in vivo and in vitro, indicate significant elevations of phosphatidylcholines in the prefontal cortex, 22 significantly reduced choline in the frontal lobe, 23 and reduced DHA in the orbitofrontal cortex 24 in BPD individuals. In sum, there is evidence for alterations in phospholipids and their fatty acids in BPD and MDD. The direction of those alterations is currently unclear, probably in part because of heterogeneity in methods and patient populations, although a recent and large study on this topic, which utilized plasma-based lipid levels, documented an inverse relationship between phospholipid levels and symptoms of depression. 26 The present study is the first to examine the influence of genetic liability for BPD on serum-based phospholipids. 
| METHODS

| Participants
| Diagnostic assessment
The Mini-International Neuropsychiatric Interview (MINI
41
), a semistructured interview, was administered to all participants. Interviews were conducted by masters-and doctorate-level research staff, who had established reliability for diagnosing bipolar disorder (κ≥0.85).
Subjects who reported possible pathology were discussed in case conference meetings with licensed psychologists and/or psychiatrists.
Consensus diagnoses were determined using available medical records, the MINI, and the interviewer's narrative.
| Lipid extraction and analysis procedure
The lipid extraction procedure used in this sample has been described in detail elsewhere. 42, 43 Briefly, lipid extraction in the SAFS is part of an ongoing longitudinal observational investigation comprising four phases of data collection during a 23-year period. The lipidomic data used in the present study were collected during the first phase, between the years 1992 and 1996. The order of the plasma samples was randomized prior to lipid extraction and analysis for each cohort.
Quality control plasma samples were included at a ratio of 1:18. Total lipid extraction from a 10-mL aliquot of plasma was performed in a single-phase chloroform:methanol (2:1) extraction.
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Lipid analysis was performed using liquid chromatography−electrospray ionization tandem mass spectrometry using an Agilent 1200 liquid chromatography system (Agilent Technologies, Santa Clara, CA, USA) combined with an Applied Biosystems API 4000 Q/TRAP mass spectrometer with a turbo-ionspray source (350 uC) and the Analyst 1.5 data system. 44 We have previously reported the use of precursor ion and neutral loss scans on control plasma extracts to identify the predominant lipid species of the following phospholipid classes: sphin-
activating factor], phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS), and phosphatidylglycerol (PG).
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Multiple reaction monitoring (MRM) experiments were established for the major species of each lipid class identified in plasma.
Relative lipid amounts were calculated by relating the peak area of each species to the peak area of the corresponding stable isotope or non-physiological internal standard. Total lipid classes were calculated from the sum of the individual lipid species within each class. 
| Quantitative genetic analysis
All genetic analyses were performed in SOLAR. 47 SOLAR implements a maximum likelihood variance decomposition to determine the proportion of variation in a phenotype due to genetic and environmental influences by modeling the covariance amongst family members as a function of genetic proximity. The simplest such decomposition is one where the additive genetic contribution of a trait is indexed by the heritability, or h 2 . All lipid classes were subject to univariate decomposition analysis to ensure that they were significantly heritable.
| Genetic correlation between BPD and lipid classes: the mean-based endophenotype ranking value (mERV)
The mean-based endophenotype ranking value (mERV) represents an extension of the ERV. The ERV, an effect size ranging between 0 and 1, was developed for the purpose of formally testing endophenotypic status of phenotypes and to rank phenotypes by their standardized genetic covariance with a disease of interest; it is expressed as follows:
where
is the heritability of the endophenotype, and ρ G is the genetic correlation between the two. 48 The mERV is an extension of the ERV to be used when the disease of interest is not sufficiently common in the data. For .
We tested the potential influence of confounding variables, in particular BMI and major depressive disorder (MDD), on all lipid classes.
We tested the potential genetic overlap, using a bivariate polygenic model, between the lipids and potential psychiatric and metabolic confounds. We then included those covariates with a significant genetic overlap with the lipid class, using a liberal threshold of P<.10 in order to increase confidence that important covariates were included in the univariate polygenic model described above in addition to the BPD coefficient of relationship (which was fixed in the model). We tested the following variables that were collected at the time of blood sampling as part of the SAFS assessment
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: body mass index (BMI); diabetes status; ever had a heart attack; smoking status; and hypertension status. In addition, we investigated the following variables from the GOBS assessment taken from the MINI
41
: any depressive disorder; any anxiety disorder; any alcohol use disorder; any substance use disorder.
| RESULTS
| Family profiles
According to our consensus diagnoses, nine individuals met the criteria of our broad BPD phenotype, four individuals met the criteria for BPD I and five met the criteria for BPD II. 
| Indexing genetic relatedness between BPD liability and all lipid classes
The heritabilities of all lipid classes are shown in Table 3 , inspection of which indicates that each class is significantly heritable. Also shown in Table 3 In general, it appears that the PI levels vary as a function of genetic proximity to an affected individual. It is important to note that cases were not included in the analyses outlined above, and thus their seemingly anomalous PI levels should not be of concern; firstly there are only nine cases and secondly their PI levels are subject to confounding factors such as mood-stabilizing medication.
| DISCUSSION
In the present study, we investigated the relative genetic overlap between BPD risk and 13 phospholipid classes; this was in an effort to rank the phospholipids according to which might be most informative when attempting to disentangle the etiology of BPD. To our knowledge, this is the first study to investigate possible genetic overlap between BPD risk and serum phospholipid levels. The existence of significant genetic overlap between BPD risk and phospholipid levels, and more specifically between illness risk and PI, strongly suggests that PI is not merely a secondary manifestation of either illness state or treatment but rather an endophenotypic marker of the illness with the potential for aiding early detection and diagnosis, as well as enhanced treatment regimens.
Phosphatidylinositols are membrane phospholipids found mostly on the inner leaflet of the cell and are characterized by an inositol ring, or head group, extending into the cytoplasm. 52 Despite their relatively low abundance compared to other membrane lipids, it is the metabolism of this phospholipid class which gives rise to second messengers which are major contributors to the myriad aspects of cellular regulation that make up the PI signal transduction pathway. 53, 54 PI is implicated in well-characterized signal transduction pathways, alterations in the molecular components of which, in particular Phosphatidylinositol 4,5-bisphosphate (PIP 2 ) and protein kinase C levels, have been previously associated with BPD. 31, 37, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] The present study, to our knowledge, is the first to suggest a shared etiology between serum PI levels and risk for BPD. PI is a particularly interesting candidate endophenotype for BPD given that lithium (Li+), a mood-stabilizing drug and treatment of choice for BPD, 66 is thought to act upon the PI signaling pathway. The inositol-depletion hypothesis posits that lithium acts by preventing the production of PI via inhibition of inositol monophosphatase, thereby limiting turnover of inositol in the cell. 29, 66 The direction of the relationship between BPD risk and PI in the present study was negative, meaning that heightened risk for BPD was associated with low levels of the phospholipid. This is the only study, to our knowledge, to assess phospholipid levels in serum in relation to BPD risk. However, Demirkan and colleagues also showed a negative correlation between plasma-based phospholipids (phosphatidylcholine and sphingomyelin) and symptoms of depression and anxiety.
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Therefore, while our results are seemingly in keeping with the previous 
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Future work might attempt to determine the levels of phospholipids in the brain and even the relationship between phospholipid levels in the brain and in the periphery. One such line of research might utilize phosphorous-31 magnetic resonance spectroscopy (31P MRS), an imaging method that allows non-invasive measurement of biological compounds (e.g. phospholipids) in vivo. In BPD, this technique has been used to demonstrate significantly reduced choline, indicating altered phospholipid metabolism, in the frontal lobe. 23 The phosphomonester (PME) signal in 31P MRS reflects the level of phosphocholine and phosphoethanolamine in addition to choline and myo-inositol; 70 there is evidence to suggest that the PME signal increases during manic states and decreases during depressed states. 33, [71] [72] [73] Thus, in addition to the unknown relationship between phospholipid levels in the periphery and brain, it is possible that a second level of complexity exists where levels in both are affected by BPD illness phase. Evidence from post-mortem studies for phospholipid alterations in the brain in BPD is mixed; in some studies, alterations in phospholipids and/or their fatty acids have not been observed in BPD subjects versus controls, [74] [75] [76] while in other studies such alterations have been observed. 24, 77 There is little consistency in terms of the focal brain region across these studies, which may explain the inconsistencies in the results. In addition, it is possible that lipidomic abnormalities in relation to affective disorders may be characterized differently in other ethnic populations. For example, non-Hispanic populations exhibit altered lipidomic profiles and associated risk for myocardial infarcation relative to Hispanics.
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Thus, overall, it is important that the generalizability of the findings of the present study should be further tested in future research.
In the present study, there was a gap in time between the collection of the lipidomic data and the occurrence of the psychiatric assessments. There is relatively little known about the longitudinal variability of serum phospholipid levels. There is evidence to suggest that phospholipids vary as a function of age, 43 and as a consequence we residualized the phospholipid traits for age (in fact for age, age 
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Two potential criticisms might be leveled at the present study regarding the affected individuals. The first criticism is that no two affected individuals with BPD occur in the same family, thus negating the idea that genetic factors underlie the illness. However, the heritability of BPD is not in question, having been established by numerous family-based studies and large genome wide association studies previously. The ERV is the product of three terms: the square root of the heritability of the endophenotype, the square root of the heritability of the disease, and the absolute value of the genetic correlation between the two. Similarly, the power of the ERV is a function of all three of these components, in the same way that the power of a genetic correlation is.
While the heritability of the endophenotypes (i.e. the phospholipid class)
can be directly estimated in the present sample, the heritability of BPD cannot, given that we have nine affected individuals. For a single endophenotype, the heritability of BPD is not identifiable (in the statistical sense) with this method. However, in principle with enough endophenotypes, the heritability of BPD may be estimable from the method due to the constraints on the parameter spaces of both the heritability and the genetic correlation, but it would generally be difficult to resolve. The total ERV, which our inference of genetic correlation/pleiotropy is based upon, is well estimated in the design. One of the substantial benefits of this method of calculating the ERV is that it does not require affected relatives of cases and thus is very useful for studying genetic determinants (shared via endophenotypes) of low-frequency diseases.
In summary, the findings presented here highlight PI as having a 
